Table 4 The league table for ORR estimates interventions according to their relative effects in first part network analysis

0.37 (− 1.08,1.83)

Icrucumab+Taxane (46.8%)

1.66 (−0.02,3.33)

1.29 (− 0.44,3.01)

Pazopanib (6%)

−0.31 (−1.40,0.77)

− 0.69 (− 1.72,0.35)

−1.97 (− 3.40,-0.54)^b

Ramucirumab+Taxane (82.4%)

0.44 (− 0.54,1.43)

0.07 (−1.00,1.14)

−1.22 (− 2.57,0.14)

0.76 (0.30,1.21)

Taxane (41.5%)

0.93 (−0.60,2.46)

0.55 (−1.03,2.14)

−0.73 (−2.52,1.06)

1.24 (− 0.01,2.50)

0.49 (− 0.68,1.65)

Vandetanib+Taxane (24%)

− 0.61 (− 2.44,1.22)

−0.98 (− 2.86,0.90)

−2.27 (−4.32,-0.21)

−0.29 (− 1.91,1.32)

−1.05 (− 2.59,0.50)

−1.54 (− 3.47,0.40)

Vinflunine (84.4%)